Sales of Samsung Bioepis' autoimmune biosimilars Benepali, Imraldi and Flixabi in Europe last year jumped 35% to a record high, reported Pulse.
According to a report released by Biogen, which owns half of the Korea-based biosimilar maker, sales of Benepali, Imraldi and Flixabi totaled $738.3 million in Europe in 2019.
Benepali, a biosimilar referencing Amgen and Pfizer's Enbrel, generated sales of $486.2 million.
Imraldi, a biosimilar version of AbbVie's Humira, recorded sales of $184 million, while Fixabi, which references Johnson & Johnson's Remicade, garnered $68 million in sales.
Samsung Bioepis said Benepali, launched in the first quarter of 2016, is outselling the original drug Enbrel in some key European markets, with largest market share in Germany, France, the UK, Italy and Spain.
To read more NewsPoints articles, click here.